nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—GJA1—dilated cardiomyopathy	0.302	0.421	CbGaD
Carvedilol—NPPB—dilated cardiomyopathy	0.302	0.421	CbGaD
Carvedilol—ADRB1—dilated cardiomyopathy	0.0616	0.086	CbGaD
Carvedilol—ADRB2—dilated cardiomyopathy	0.0518	0.0723	CbGaD
Carvedilol—GJA1—sinoatrial node—dilated cardiomyopathy	0.0165	0.199	CbGeAlD
Carvedilol—NPPB—pulmonary artery—dilated cardiomyopathy	0.0121	0.147	CbGeAlD
Carvedilol—KCNH2—purkinje fiber—dilated cardiomyopathy	0.00964	0.117	CbGeAlD
Carvedilol—KCNH2—endocardium—dilated cardiomyopathy	0.00497	0.0601	CbGeAlD
Carvedilol—CYP2C9—cardial valve—dilated cardiomyopathy	0.00404	0.0488	CbGeAlD
Carvedilol—NPN increased—Lisinopril—dilated cardiomyopathy	0.00369	0.0413	CcSEcCtD
Carvedilol—ABCB1—Lisinopril—dilated cardiomyopathy	0.0029	0.532	CbGbCtD
Carvedilol—ABCB1—Spironolactone—dilated cardiomyopathy	0.00256	0.468	CbGbCtD
Carvedilol—Acute myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00253	0.0283	CcSEcCtD
Carvedilol—NPPB—cardiac ventricle—dilated cardiomyopathy	0.00252	0.0305	CbGeAlD
Carvedilol—NPPB—myocardium—dilated cardiomyopathy	0.00237	0.0287	CbGeAlD
Carvedilol—Glucose tolerance impaired—Furosemide—dilated cardiomyopathy	0.00229	0.0256	CcSEcCtD
Carvedilol—Hypovolaemia—Furosemide—dilated cardiomyopathy	0.00199	0.0223	CcSEcCtD
Carvedilol—NPPB—heart—dilated cardiomyopathy	0.00165	0.02	CbGeAlD
Carvedilol—SELE—myocardium—dilated cardiomyopathy	0.0016	0.0194	CbGeAlD
Carvedilol—HIF1A—cardiac ventricle—dilated cardiomyopathy	0.00151	0.0182	CbGeAlD
Carvedilol—Rash erythematous—Spironolactone—dilated cardiomyopathy	0.00148	0.0166	CcSEcCtD
Carvedilol—VCAM1—myocardium—dilated cardiomyopathy	0.00147	0.0178	CbGeAlD
Carvedilol—GJA1—cardiac ventricle—dilated cardiomyopathy	0.00146	0.0177	CbGeAlD
Carvedilol—GJA1—Cortisone acetate—Spironolactone—dilated cardiomyopathy	0.00143	0.446	CbGdCrCtD
Carvedilol—HIF1A—myocardium—dilated cardiomyopathy	0.00142	0.0171	CbGeAlD
Carvedilol—NPPB—cardiac atrium—dilated cardiomyopathy	0.00141	0.0171	CbGeAlD
Carvedilol—Diabetic—Lisinopril—dilated cardiomyopathy	0.00139	0.0155	CcSEcCtD
Carvedilol—GJA1—myocardium—dilated cardiomyopathy	0.00137	0.0166	CbGeAlD
Carvedilol—Atrioventricular block complete—Lisinopril—dilated cardiomyopathy	0.00132	0.0148	CcSEcCtD
Carvedilol—Ranolazine—SCN5A—dilated cardiomyopathy	0.00123	0.281	CrCbGaD
Carvedilol—VEGFA—cardiac ventricle—dilated cardiomyopathy	0.00115	0.014	CbGeAlD
Carvedilol—SELE—heart—dilated cardiomyopathy	0.00112	0.0135	CbGeAlD
Carvedilol—Hyperkalaemia—Spironolactone—dilated cardiomyopathy	0.00111	0.0125	CcSEcCtD
Carvedilol—VEGFA—myocardium—dilated cardiomyopathy	0.00109	0.0131	CbGeAlD
Carvedilol—Cerebration impaired—Furosemide—dilated cardiomyopathy	0.00105	0.0117	CcSEcCtD
Carvedilol—Cramps of lower extremities—Spironolactone—dilated cardiomyopathy	0.00104	0.0117	CcSEcCtD
Carvedilol—VCAM1—heart—dilated cardiomyopathy	0.00103	0.0124	CbGeAlD
Carvedilol—HIF1A—heart—dilated cardiomyopathy	0.000989	0.012	CbGeAlD
Carvedilol—GJA1—heart—dilated cardiomyopathy	0.000959	0.0116	CbGeAlD
Carvedilol—Blood triglycerides increased—Furosemide—dilated cardiomyopathy	0.000941	0.0105	CcSEcCtD
Carvedilol—Renal failure acute—Spironolactone—dilated cardiomyopathy	0.000891	0.00997	CcSEcCtD
Carvedilol—VCAM1—cardiac atrium—dilated cardiomyopathy	0.000879	0.0106	CbGeAlD
Carvedilol—HIF1A—cardiac atrium—dilated cardiomyopathy	0.000846	0.0102	CbGeAlD
Carvedilol—NDUFC2—heart—dilated cardiomyopathy	0.000835	0.0101	CbGeAlD
Carvedilol—Sleep disturbance—Lisinopril—dilated cardiomyopathy	0.000825	0.00924	CcSEcCtD
Carvedilol—GJA1—cardiac atrium—dilated cardiomyopathy	0.00082	0.00992	CbGeAlD
Carvedilol—Generalised oedema—Lisinopril—dilated cardiomyopathy	0.000777	0.0087	CcSEcCtD
Carvedilol—Glycosuria—Furosemide—dilated cardiomyopathy	0.000761	0.00852	CcSEcCtD
Carvedilol—VEGFA—heart—dilated cardiomyopathy	0.000757	0.00916	CbGeAlD
Carvedilol—Fluid overload—Lisinopril—dilated cardiomyopathy	0.000744	0.00833	CcSEcCtD
Carvedilol—Cramp muscle—Spironolactone—dilated cardiomyopathy	0.000741	0.00829	CcSEcCtD
Carvedilol—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.000741	0.00829	CcSEcCtD
Carvedilol—Psoriasis—Lisinopril—dilated cardiomyopathy	0.000736	0.00824	CcSEcCtD
Carvedilol—NDUFC2—cardiac atrium—dilated cardiomyopathy	0.000714	0.00864	CbGeAlD
Carvedilol—Disturbance in attention—Furosemide—dilated cardiomyopathy	0.000711	0.00796	CcSEcCtD
Carvedilol—GJA1—Progesterone—Spironolactone—dilated cardiomyopathy	0.000698	0.218	CbGdCrCtD
Carvedilol—Propafenone—SCN5A—dilated cardiomyopathy	0.000671	0.154	CrCbGaD
Carvedilol—Hyperuricaemia—Furosemide—dilated cardiomyopathy	0.000664	0.00744	CcSEcCtD
Carvedilol—Gout—Furosemide—dilated cardiomyopathy	0.00066	0.00739	CcSEcCtD
Carvedilol—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.000655	0.00733	CcSEcCtD
Carvedilol—VEGFA—cardiac atrium—dilated cardiomyopathy	0.000648	0.00783	CbGeAlD
Carvedilol—Hearing impaired—Furosemide—dilated cardiomyopathy	0.000647	0.00725	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.000628	0.00703	CcSEcCtD
Carvedilol—Blood uric acid increased—Furosemide—dilated cardiomyopathy	0.000628	0.00703	CcSEcCtD
Carvedilol—Renal failure—Spironolactone—dilated cardiomyopathy	0.000623	0.00697	CcSEcCtD
Carvedilol—Ventricular fibrillation—Lisinopril—dilated cardiomyopathy	0.000604	0.00676	CcSEcCtD
Carvedilol—Aplastic anaemia—Furosemide—dilated cardiomyopathy	0.000579	0.00648	CcSEcCtD
Carvedilol—GJA1—Enalapril—Lisinopril—dilated cardiomyopathy	0.00057	0.178	CbGdCrCtD
Carvedilol—Cramps of lower extremities—Furosemide—dilated cardiomyopathy	0.000566	0.00634	CcSEcCtD
Carvedilol—Lightheadedness—Furosemide—dilated cardiomyopathy	0.000551	0.00617	CcSEcCtD
Carvedilol—ADRB1—cardiac ventricle—dilated cardiomyopathy	0.000547	0.00662	CbGeAlD
Carvedilol—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.000538	0.00602	CcSEcCtD
Carvedilol—Mental disability—Furosemide—dilated cardiomyopathy	0.000535	0.00599	CcSEcCtD
Carvedilol—Bevantolol—ADRB1—dilated cardiomyopathy	0.000526	0.12	CrCbGaD
Carvedilol—Accidental injury—Lisinopril—dilated cardiomyopathy	0.000523	0.00585	CcSEcCtD
Carvedilol—ADRB1—myocardium—dilated cardiomyopathy	0.000515	0.00623	CbGeAlD
Carvedilol—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.000514	0.00576	CcSEcCtD
Carvedilol—Viral infection—Lisinopril—dilated cardiomyopathy	0.000512	0.00573	CcSEcCtD
Carvedilol—Swelling—Furosemide—dilated cardiomyopathy	0.000507	0.00568	CcSEcCtD
Carvedilol—Cough increased—Lisinopril—dilated cardiomyopathy	0.000505	0.00566	CcSEcCtD
Carvedilol—Alopecia—Spironolactone—dilated cardiomyopathy	0.000503	0.00563	CcSEcCtD
Carvedilol—VEGFA—Enalapril—Lisinopril—dilated cardiomyopathy	0.000502	0.157	CbGdCrCtD
Carvedilol—Vascular purpura—Furosemide—dilated cardiomyopathy	0.0005	0.0056	CcSEcCtD
Carvedilol—Gout—Lisinopril—dilated cardiomyopathy	0.000495	0.00554	CcSEcCtD
Carvedilol—Bopindolol—ADRB1—dilated cardiomyopathy	0.000487	0.112	CrCbGaD
Carvedilol—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.000486	0.00544	CcSEcCtD
Carvedilol—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.000476	0.00533	CcSEcCtD
Carvedilol—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.000474	0.00531	CcSEcCtD
Carvedilol—Purpura—Furosemide—dilated cardiomyopathy	0.000464	0.0052	CcSEcCtD
Carvedilol—Ventricular tachycardia—Lisinopril—dilated cardiomyopathy	0.000462	0.00518	CcSEcCtD
Carvedilol—Anaphylactoid reaction—Furosemide—dilated cardiomyopathy	0.000462	0.00517	CcSEcCtD
Carvedilol—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.000459	0.00514	CcSEcCtD
Carvedilol—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.000454	0.00509	CcSEcCtD
Carvedilol—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.000449	0.00503	CcSEcCtD
Carvedilol—Wheezing—Lisinopril—dilated cardiomyopathy	0.000449	0.00503	CcSEcCtD
Carvedilol—Malaise—Spironolactone—dilated cardiomyopathy	0.000447	0.005	CcSEcCtD
Carvedilol—Leukopenia—Spironolactone—dilated cardiomyopathy	0.000443	0.00496	CcSEcCtD
Carvedilol—Bevantolol—ADRB2—dilated cardiomyopathy	0.000443	0.101	CrCbGaD
Carvedilol—Fluid retention—Lisinopril—dilated cardiomyopathy	0.000439	0.00491	CcSEcCtD
Carvedilol—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.000437	0.00489	CcSEcCtD
Carvedilol—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.000419	0.00469	CcSEcCtD
Carvedilol—KCNH2—cardiac ventricle—dilated cardiomyopathy	0.000418	0.00506	CbGeAlD
Carvedilol—Discomfort—Spironolactone—dilated cardiomyopathy	0.000417	0.00466	CcSEcCtD
Carvedilol—Dehydration—Furosemide—dilated cardiomyopathy	0.000416	0.00466	CcSEcCtD
Carvedilol—Lightheadedness—Lisinopril—dilated cardiomyopathy	0.000414	0.00463	CcSEcCtD
Carvedilol—ADRA2C—cardiac ventricle—dilated cardiomyopathy	0.000412	0.00499	CbGeAlD
Carvedilol—Pulmonary oedema—Lisinopril—dilated cardiomyopathy	0.000412	0.00461	CcSEcCtD
Carvedilol—Bopindolol—ADRB2—dilated cardiomyopathy	0.00041	0.0938	CrCbGaD
Carvedilol—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.000409	0.00457	CcSEcCtD
Carvedilol—Confusional state—Spironolactone—dilated cardiomyopathy	0.000408	0.00456	CcSEcCtD
Carvedilol—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.000407	0.00456	CcSEcCtD
Carvedilol—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.000404	0.00452	CcSEcCtD
Carvedilol—Cramp muscle—Furosemide—dilated cardiomyopathy	0.000403	0.00451	CcSEcCtD
Carvedilol—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.000403	0.00451	CcSEcCtD
Carvedilol—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.000396	0.00443	CcSEcCtD
Carvedilol—KCNH2—myocardium—dilated cardiomyopathy	0.000393	0.00476	CbGeAlD
Carvedilol—ADRA2C—myocardium—dilated cardiomyopathy	0.000388	0.00469	CbGeAlD
Carvedilol—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.000388	0.00434	CcSEcCtD
Carvedilol—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.000386	0.00432	CcSEcCtD
Carvedilol—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.000368	0.00413	CcSEcCtD
Carvedilol—Injury—Lisinopril—dilated cardiomyopathy	0.000365	0.00409	CcSEcCtD
Carvedilol—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.000364	0.00407	CcSEcCtD
Carvedilol—Libido decreased—Lisinopril—dilated cardiomyopathy	0.000362	0.00405	CcSEcCtD
Carvedilol—ADRB1—heart—dilated cardiomyopathy	0.000359	0.00435	CbGeAlD
Carvedilol—Somnolence—Spironolactone—dilated cardiomyopathy	0.000359	0.00402	CcSEcCtD
Carvedilol—Pollakiuria—Furosemide—dilated cardiomyopathy	0.000357	0.004	CcSEcCtD
Carvedilol—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.000354	0.00397	CcSEcCtD
Carvedilol—CYP1A1—cardiac ventricle—dilated cardiomyopathy	0.000353	0.00427	CbGeAlD
Carvedilol—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.000353	0.00395	CcSEcCtD
Carvedilol—Renal impairment—Lisinopril—dilated cardiomyopathy	0.000353	0.00395	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000349	0.00391	CcSEcCtD
Carvedilol—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.000349	0.0039	CcSEcCtD
Carvedilol—Anaphylactoid reaction—Lisinopril—dilated cardiomyopathy	0.000347	0.00388	CcSEcCtD
Carvedilol—Arthritis—Lisinopril—dilated cardiomyopathy	0.000345	0.00387	CcSEcCtD
Carvedilol—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.000344	0.00385	CcSEcCtD
Carvedilol—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.000343	0.00383	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.000342	0.00383	CcSEcCtD
Carvedilol—Renal failure—Furosemide—dilated cardiomyopathy	0.000339	0.00379	CcSEcCtD
Carvedilol—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.000337	0.00377	CcSEcCtD
Carvedilol—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.000336	0.00376	CcSEcCtD
Carvedilol—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.000333	0.00373	CcSEcCtD
Carvedilol—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.000333	0.00373	CcSEcCtD
Carvedilol—Urticaria—Spironolactone—dilated cardiomyopathy	0.000321	0.00359	CcSEcCtD
Carvedilol—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00032	0.00358	CcSEcCtD
Carvedilol—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.000319	0.00357	CcSEcCtD
Carvedilol—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.000314	0.00352	CcSEcCtD
Carvedilol—Dehydration—Lisinopril—dilated cardiomyopathy	0.000312	0.00349	CcSEcCtD
Carvedilol—ADRB1—cardiac atrium—dilated cardiomyopathy	0.000307	0.00372	CbGeAlD
Carvedilol—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.000307	0.00343	CcSEcCtD
Carvedilol—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.000306	0.00342	CcSEcCtD
Carvedilol—Urethral disorder—Furosemide—dilated cardiomyopathy	0.000303	0.0034	CcSEcCtD
Carvedilol—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.000302	0.00338	CcSEcCtD
Carvedilol—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.000302	0.00338	CcSEcCtD
Carvedilol—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.0003	0.00336	CcSEcCtD
Carvedilol—Visual impairment—Furosemide—dilated cardiomyopathy	0.000298	0.00334	CcSEcCtD
Carvedilol—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000298	0.00333	CcSEcCtD
Carvedilol—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.000293	0.00328	CcSEcCtD
Carvedilol—PTGS1—myocardium—dilated cardiomyopathy	0.000292	0.00353	CbGeAlD
Carvedilol—Influenza—Lisinopril—dilated cardiomyopathy	0.00029	0.00325	CcSEcCtD
Carvedilol—Tinnitus—Furosemide—dilated cardiomyopathy	0.000289	0.00323	CcSEcCtD
Carvedilol—Pruritus—Spironolactone—dilated cardiomyopathy	0.000286	0.0032	CcSEcCtD
Carvedilol—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.000285	0.00319	CcSEcCtD
Carvedilol—ADRA1A—heart—dilated cardiomyopathy	0.000284	0.00344	CbGeAlD
Carvedilol—Sweating increased—Lisinopril—dilated cardiomyopathy	0.000283	0.00316	CcSEcCtD
Carvedilol—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.000283	0.00316	CcSEcCtD
Carvedilol—Angiopathy—Furosemide—dilated cardiomyopathy	0.000281	0.00314	CcSEcCtD
Carvedilol—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00028	0.00313	CcSEcCtD
Carvedilol—Bronchitis—Lisinopril—dilated cardiomyopathy	0.000279	0.00312	CcSEcCtD
Carvedilol—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000277	0.0031	CcSEcCtD
Carvedilol—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.000276	0.00308	CcSEcCtD
Carvedilol—KCNH2—heart—dilated cardiomyopathy	0.000274	0.00332	CbGeAlD
Carvedilol—ADRA2C—heart—dilated cardiomyopathy	0.000271	0.00328	CbGeAlD
Carvedilol—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00027	0.00302	CcSEcCtD
Carvedilol—Malnutrition—Furosemide—dilated cardiomyopathy	0.000269	0.00302	CcSEcCtD
Carvedilol—Dizziness—Spironolactone—dilated cardiomyopathy	0.000267	0.00299	CcSEcCtD
Carvedilol—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.000267	0.00299	CcSEcCtD
Carvedilol—Propafenone—ADRB1—dilated cardiomyopathy	0.000267	0.0611	CrCbGaD
Carvedilol—Flatulence—Furosemide—dilated cardiomyopathy	0.000265	0.00297	CcSEcCtD
Carvedilol—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.000265	0.00296	CcSEcCtD
Carvedilol—Weight increased—Lisinopril—dilated cardiomyopathy	0.000264	0.00296	CcSEcCtD
Carvedilol—Weight decreased—Lisinopril—dilated cardiomyopathy	0.000262	0.00294	CcSEcCtD
Carvedilol—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.000262	0.00293	CcSEcCtD
Carvedilol—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00026	0.00291	CcSEcCtD
Carvedilol—Muscle spasms—Furosemide—dilated cardiomyopathy	0.000259	0.0029	CcSEcCtD
Carvedilol—Depression—Lisinopril—dilated cardiomyopathy	0.000258	0.00289	CcSEcCtD
Carvedilol—Vomiting—Spironolactone—dilated cardiomyopathy	0.000257	0.00288	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.000256	0.00287	CcSEcCtD
Carvedilol—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.000255	0.00285	CcSEcCtD
Carvedilol—Rash—Spironolactone—dilated cardiomyopathy	0.000255	0.00285	CcSEcCtD
Carvedilol—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000255	0.00285	CcSEcCtD
Carvedilol—Renal failure—Lisinopril—dilated cardiomyopathy	0.000254	0.00285	CcSEcCtD
Carvedilol—Vision blurred—Furosemide—dilated cardiomyopathy	0.000254	0.00284	CcSEcCtD
Carvedilol—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.000254	0.00284	CcSEcCtD
Carvedilol—Headache—Spironolactone—dilated cardiomyopathy	0.000253	0.00283	CcSEcCtD
Carvedilol—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.000251	0.00281	CcSEcCtD
Carvedilol—Anaemia—Furosemide—dilated cardiomyopathy	0.000249	0.00279	CcSEcCtD
Carvedilol—Haematuria—Lisinopril—dilated cardiomyopathy	0.000247	0.00276	CcSEcCtD
Carvedilol—Sinusitis—Lisinopril—dilated cardiomyopathy	0.000243	0.00272	CcSEcCtD
Carvedilol—Vertigo—Furosemide—dilated cardiomyopathy	0.000242	0.00271	CcSEcCtD
Carvedilol—Leukopenia—Furosemide—dilated cardiomyopathy	0.000241	0.0027	CcSEcCtD
Carvedilol—Nausea—Spironolactone—dilated cardiomyopathy	0.00024	0.00269	CcSEcCtD
Carvedilol—Bradycardia—Lisinopril—dilated cardiomyopathy	0.000236	0.00265	CcSEcCtD
Carvedilol—KCNH2—cardiac atrium—dilated cardiomyopathy	0.000235	0.00284	CbGeAlD
Carvedilol—Rhinitis—Lisinopril—dilated cardiomyopathy	0.000233	0.00261	CcSEcCtD
Carvedilol—CYP1A1—heart—dilated cardiomyopathy	0.000232	0.0028	CbGeAlD
Carvedilol—ADRA2C—cardiac atrium—dilated cardiomyopathy	0.000232	0.0028	CbGeAlD
Carvedilol—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00023	0.00258	CcSEcCtD
Carvedilol—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000229	0.00257	CcSEcCtD
Carvedilol—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000229	0.00256	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.000228	0.00255	CcSEcCtD
Carvedilol—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.000228	0.00255	CcSEcCtD
Carvedilol—Dry mouth—Furosemide—dilated cardiomyopathy	0.000224	0.00251	CcSEcCtD
Carvedilol—CYP2C9—heart—dilated cardiomyopathy	0.000223	0.0027	CbGeAlD
Carvedilol—Confusional state—Furosemide—dilated cardiomyopathy	0.000222	0.00248	CcSEcCtD
Carvedilol—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00022	0.00246	CcSEcCtD
Carvedilol—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00022	0.00246	CcSEcCtD
Carvedilol—Tinnitus—Lisinopril—dilated cardiomyopathy	0.000217	0.00242	CcSEcCtD
Carvedilol—Shock—Furosemide—dilated cardiomyopathy	0.000216	0.00242	CcSEcCtD
Carvedilol—ADRA2A—heart—dilated cardiomyopathy	0.000216	0.00261	CbGeAlD
Carvedilol—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000215	0.00241	CcSEcCtD
Carvedilol—Skin disorder—Furosemide—dilated cardiomyopathy	0.000214	0.00239	CcSEcCtD
Carvedilol—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000213	0.00238	CcSEcCtD
Carvedilol—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000211	0.00236	CcSEcCtD
Carvedilol—Anorexia—Furosemide—dilated cardiomyopathy	0.00021	0.00235	CcSEcCtD
Carvedilol—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000209	0.00234	CcSEcCtD
Carvedilol—Hypotension—Furosemide—dilated cardiomyopathy	0.000205	0.0023	CcSEcCtD
Carvedilol—Alopecia—Lisinopril—dilated cardiomyopathy	0.000205	0.0023	CcSEcCtD
Carvedilol—PTGS1—heart—dilated cardiomyopathy	0.000204	0.00246	CbGeAlD
Carvedilol—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000202	0.00226	CcSEcCtD
Carvedilol—Flatulence—Lisinopril—dilated cardiomyopathy	0.000199	0.00223	CcSEcCtD
Carvedilol—Tension—Lisinopril—dilated cardiomyopathy	0.000198	0.00222	CcSEcCtD
Carvedilol—CYP1A1—cardiac atrium—dilated cardiomyopathy	0.000198	0.0024	CbGeAlD
Carvedilol—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000197	0.00221	CcSEcCtD
Carvedilol—Nervousness—Lisinopril—dilated cardiomyopathy	0.000196	0.0022	CcSEcCtD
Carvedilol—Back pain—Lisinopril—dilated cardiomyopathy	0.000196	0.00219	CcSEcCtD
Carvedilol—Somnolence—Furosemide—dilated cardiomyopathy	0.000195	0.00219	CcSEcCtD
Carvedilol—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000194	0.00218	CcSEcCtD
Carvedilol—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000191	0.00214	CcSEcCtD
Carvedilol—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000191	0.00213	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00019	0.00213	CcSEcCtD
Carvedilol—Fatigue—Furosemide—dilated cardiomyopathy	0.00019	0.00212	CcSEcCtD
Carvedilol—Pain—Furosemide—dilated cardiomyopathy	0.000188	0.00211	CcSEcCtD
Carvedilol—Constipation—Furosemide—dilated cardiomyopathy	0.000188	0.00211	CcSEcCtD
Carvedilol—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.000188	0.0021	CcSEcCtD
Carvedilol—Anaemia—Lisinopril—dilated cardiomyopathy	0.000187	0.00209	CcSEcCtD
Carvedilol—ADRA2A—cardiac atrium—dilated cardiomyopathy	0.000185	0.00224	CbGeAlD
Carvedilol—Angioedema—Lisinopril—dilated cardiomyopathy	0.000185	0.00207	CcSEcCtD
Carvedilol—Propranolol—ADRB1—dilated cardiomyopathy	0.000183	0.0419	CrCbGaD
Carvedilol—Malaise—Lisinopril—dilated cardiomyopathy	0.000182	0.00204	CcSEcCtD
Carvedilol—Vertigo—Lisinopril—dilated cardiomyopathy	0.000182	0.00203	CcSEcCtD
Carvedilol—Syncope—Lisinopril—dilated cardiomyopathy	0.000181	0.00203	CcSEcCtD
Carvedilol—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000181	0.00203	CcSEcCtD
Carvedilol—Leukopenia—Lisinopril—dilated cardiomyopathy	0.000181	0.00203	CcSEcCtD
Carvedilol—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00018	0.00201	CcSEcCtD
Carvedilol—Palpitations—Lisinopril—dilated cardiomyopathy	0.000179	0.002	CcSEcCtD
Carvedilol—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.000178	0.00199	CcSEcCtD
Carvedilol—Cough—Lisinopril—dilated cardiomyopathy	0.000176	0.00197	CcSEcCtD
Carvedilol—Urticaria—Furosemide—dilated cardiomyopathy	0.000175	0.00196	CcSEcCtD
Carvedilol—PTGS1—cardiac atrium—dilated cardiomyopathy	0.000174	0.00211	CbGeAlD
Carvedilol—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000174	0.00195	CcSEcCtD
Carvedilol—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000174	0.00195	CcSEcCtD
Carvedilol—Chest pain—Lisinopril—dilated cardiomyopathy	0.000172	0.00193	CcSEcCtD
Carvedilol—Myalgia—Lisinopril—dilated cardiomyopathy	0.000172	0.00193	CcSEcCtD
Carvedilol—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000172	0.00193	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000171	0.00191	CcSEcCtD
Carvedilol—Discomfort—Lisinopril—dilated cardiomyopathy	0.00017	0.0019	CcSEcCtD
Carvedilol—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000168	0.00188	CcSEcCtD
Carvedilol—Confusional state—Lisinopril—dilated cardiomyopathy	0.000166	0.00186	CcSEcCtD
Carvedilol—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.000165	0.00185	CcSEcCtD
Carvedilol—Oedema—Lisinopril—dilated cardiomyopathy	0.000165	0.00185	CcSEcCtD
Carvedilol—Infection—Lisinopril—dilated cardiomyopathy	0.000164	0.00183	CcSEcCtD
Carvedilol—Shock—Lisinopril—dilated cardiomyopathy	0.000162	0.00182	CcSEcCtD
Carvedilol—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000162	0.00181	CcSEcCtD
Carvedilol—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000162	0.00181	CcSEcCtD
Carvedilol—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000161	0.0018	CcSEcCtD
Carvedilol—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00016	0.00179	CcSEcCtD
Carvedilol—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000159	0.00179	CcSEcCtD
Carvedilol—Asthenia—Furosemide—dilated cardiomyopathy	0.000158	0.00177	CcSEcCtD
Carvedilol—Anorexia—Lisinopril—dilated cardiomyopathy	0.000157	0.00176	CcSEcCtD
Carvedilol—Pruritus—Furosemide—dilated cardiomyopathy	0.000156	0.00174	CcSEcCtD
Carvedilol—Hypotension—Lisinopril—dilated cardiomyopathy	0.000154	0.00173	CcSEcCtD
Carvedilol—Propranolol—ADRB2—dilated cardiomyopathy	0.000154	0.0352	CrCbGaD
Carvedilol—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00015	0.00168	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00015	0.00168	CcSEcCtD
Carvedilol—Insomnia—Lisinopril—dilated cardiomyopathy	0.000149	0.00167	CcSEcCtD
Carvedilol—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000148	0.00166	CcSEcCtD
Carvedilol—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000147	0.00165	CcSEcCtD
Carvedilol—Somnolence—Lisinopril—dilated cardiomyopathy	0.000147	0.00164	CcSEcCtD
Carvedilol—Dizziness—Furosemide—dilated cardiomyopathy	0.000145	0.00163	CcSEcCtD
Carvedilol—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000145	0.00163	CcSEcCtD
Carvedilol—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000143	0.00161	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000142	0.00159	CcSEcCtD
Carvedilol—Fatigue—Lisinopril—dilated cardiomyopathy	0.000142	0.00159	CcSEcCtD
Carvedilol—Pain—Lisinopril—dilated cardiomyopathy	0.000141	0.00158	CcSEcCtD
Carvedilol—Constipation—Lisinopril—dilated cardiomyopathy	0.000141	0.00158	CcSEcCtD
Carvedilol—Vomiting—Furosemide—dilated cardiomyopathy	0.00014	0.00157	CcSEcCtD
Carvedilol—Rash—Furosemide—dilated cardiomyopathy	0.000139	0.00155	CcSEcCtD
Carvedilol—Dermatitis—Furosemide—dilated cardiomyopathy	0.000139	0.00155	CcSEcCtD
Carvedilol—Headache—Furosemide—dilated cardiomyopathy	0.000138	0.00154	CcSEcCtD
Carvedilol—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000136	0.00152	CcSEcCtD
Carvedilol—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000135	0.00151	CcSEcCtD
Carvedilol—Urticaria—Lisinopril—dilated cardiomyopathy	0.000131	0.00147	CcSEcCtD
Carvedilol—Nausea—Furosemide—dilated cardiomyopathy	0.000131	0.00146	CcSEcCtD
Carvedilol—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00013	0.00146	CcSEcCtD
Carvedilol—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00013	0.00146	CcSEcCtD
Carvedilol—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000122	0.00136	CcSEcCtD
Carvedilol—ABCB1—heart—dilated cardiomyopathy	0.00012	0.00146	CbGeAlD
Carvedilol—Asthenia—Lisinopril—dilated cardiomyopathy	0.000118	0.00133	CcSEcCtD
Carvedilol—Pruritus—Lisinopril—dilated cardiomyopathy	0.000117	0.00131	CcSEcCtD
Carvedilol—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000113	0.00126	CcSEcCtD
Carvedilol—Dizziness—Lisinopril—dilated cardiomyopathy	0.000109	0.00122	CcSEcCtD
Carvedilol—Vomiting—Lisinopril—dilated cardiomyopathy	0.000105	0.00117	CcSEcCtD
Carvedilol—Rash—Lisinopril—dilated cardiomyopathy	0.000104	0.00116	CcSEcCtD
Carvedilol—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000104	0.00116	CcSEcCtD
Carvedilol—Headache—Lisinopril—dilated cardiomyopathy	0.000103	0.00116	CcSEcCtD
Carvedilol—Nausea—Lisinopril—dilated cardiomyopathy	9.8e-05	0.0011	CcSEcCtD
Carvedilol—PTGS1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.16e-05	0.000118	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR ligand binding—AGT—dilated cardiomyopathy	1.16e-05	0.000118	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—CD36—dilated cardiomyopathy	1.15e-05	0.000117	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	1.15e-05	0.000117	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	1.14e-05	0.000116	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	1.14e-05	0.000116	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	1.14e-05	0.000116	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	1.12e-05	0.000115	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	1.12e-05	0.000114	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—EGFR—dilated cardiomyopathy	1.12e-05	0.000114	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	1.12e-05	0.000114	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.12e-05	0.000114	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.11e-05	0.000113	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—AGTR1—dilated cardiomyopathy	1.11e-05	0.000113	CbGpPWpGaD
Carvedilol—XDH—Metabolism—AGT—dilated cardiomyopathy	1.1e-05	0.000112	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	1.1e-05	0.000112	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—AGTR1—dilated cardiomyopathy	1.1e-05	0.000112	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	1.1e-05	0.000112	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	1.1e-05	0.000112	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	1.09e-05	0.000111	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	1.08e-05	0.00011	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—RAC1—dilated cardiomyopathy	1.08e-05	0.00011	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	1.08e-05	0.00011	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	1.07e-05	0.000109	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—TNF—dilated cardiomyopathy	1.07e-05	0.000109	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	1.07e-05	0.000109	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—PSEN2—dilated cardiomyopathy	1.06e-05	0.000108	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	1.06e-05	0.000108	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	1.06e-05	0.000108	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.06e-05	0.000108	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.06e-05	0.000108	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—ADRB2—dilated cardiomyopathy	1.05e-05	0.000107	CbGpPWpGaD
Carvedilol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	1.05e-05	0.000107	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—AGTR1—dilated cardiomyopathy	1.04e-05	0.000106	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—AGTR1—dilated cardiomyopathy	1.02e-05	0.000104	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	1.02e-05	0.000104	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	9.99e-06	0.000102	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—RAC1—dilated cardiomyopathy	9.98e-06	0.000102	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	9.87e-06	0.000101	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—ADRB2—dilated cardiomyopathy	9.84e-06	0.0001	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	9.71e-06	9.9e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—PSEN2—dilated cardiomyopathy	9.7e-06	9.89e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—ADRB2—dilated cardiomyopathy	9.69e-06	9.87e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—PSEN2—dilated cardiomyopathy	9.61e-06	9.8e-05	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—AGT—dilated cardiomyopathy	9.53e-06	9.72e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—PSEN2—dilated cardiomyopathy	9.49e-06	9.67e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	9.48e-06	9.66e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—RAF1—dilated cardiomyopathy	9.45e-06	9.63e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—AGTR2—dilated cardiomyopathy	9.45e-06	9.63e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CXCL2—dilated cardiomyopathy	9.45e-06	9.63e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	9.29e-06	9.47e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	9.28e-06	9.46e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—RAF1—dilated cardiomyopathy	9.22e-06	9.4e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.09e-06	9.27e-05	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	9.09e-06	9.27e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.08e-06	9.25e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	9.07e-06	9.24e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—RAC1—dilated cardiomyopathy	9.06e-06	9.24e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	9.05e-06	9.22e-05	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—RAC1—dilated cardiomyopathy	9.01e-06	9.18e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—PSEN2—dilated cardiomyopathy	8.98e-06	9.15e-05	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—RAC1—dilated cardiomyopathy	8.89e-06	9.06e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—PSEN2—dilated cardiomyopathy	8.83e-06	9e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—RAF1—dilated cardiomyopathy	8.83e-06	9e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	8.81e-06	8.98e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	8.8e-06	8.97e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CXCR3—dilated cardiomyopathy	8.79e-06	8.96e-05	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—AGT—dilated cardiomyopathy	8.69e-06	8.85e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—AGT—dilated cardiomyopathy	8.66e-06	8.82e-05	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—EGFR—dilated cardiomyopathy	8.64e-06	8.81e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—AGTR2—dilated cardiomyopathy	8.61e-06	8.78e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CXCL2—dilated cardiomyopathy	8.61e-06	8.78e-05	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—AGT—dilated cardiomyopathy	8.61e-06	8.77e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	8.6e-06	8.77e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—AGTR2—dilated cardiomyopathy	8.53e-06	8.7e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CXCL2—dilated cardiomyopathy	8.53e-06	8.7e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—ADRB1—dilated cardiomyopathy	8.51e-06	8.67e-05	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—AGT—dilated cardiomyopathy	8.5e-06	8.66e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	8.43e-06	8.59e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—AGTR2—dilated cardiomyopathy	8.42e-06	8.59e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CXCL2—dilated cardiomyopathy	8.42e-06	8.59e-05	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—RAC1—dilated cardiomyopathy	8.41e-06	8.58e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	8.29e-06	8.45e-05	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—RAC1—dilated cardiomyopathy	8.28e-06	8.44e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—RAC1—dilated cardiomyopathy	8.26e-06	8.41e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—RAC1—dilated cardiomyopathy	8.22e-06	8.38e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—RAC1—dilated cardiomyopathy	8.2e-06	8.36e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—RAC1—dilated cardiomyopathy	8.18e-06	8.34e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	8.14e-06	8.3e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—RAC1—dilated cardiomyopathy	8.08e-06	8.23e-05	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—AGT—dilated cardiomyopathy	8.04e-06	8.19e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CXCR3—dilated cardiomyopathy	8.01e-06	8.16e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	7.99e-06	8.15e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CXCL2—dilated cardiomyopathy	7.97e-06	8.12e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—AGTR2—dilated cardiomyopathy	7.97e-06	8.12e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.93e-06	8.09e-05	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—AGT—dilated cardiomyopathy	7.91e-06	8.06e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—AGT—dilated cardiomyopathy	7.89e-06	8.04e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—AGT—dilated cardiomyopathy	7.85e-06	8e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—PSEN2—dilated cardiomyopathy	7.85e-06	8e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—AGTR2—dilated cardiomyopathy	7.84e-06	8e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CXCL2—dilated cardiomyopathy	7.84e-06	8e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—AGT—dilated cardiomyopathy	7.83e-06	7.98e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.83e-06	7.98e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—AGT—dilated cardiomyopathy	7.82e-06	7.97e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—AGT—dilated cardiomyopathy	7.72e-06	7.86e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.68e-06	7.83e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—RAC1—dilated cardiomyopathy	7.64e-06	7.79e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.58e-06	7.73e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—RAC1—dilated cardiomyopathy	7.52e-06	7.67e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	7.49e-06	7.64e-05	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	7.41e-06	7.56e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.41e-06	7.55e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	7.36e-06	7.5e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—AGT—dilated cardiomyopathy	7.3e-06	7.44e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.29e-06	7.43e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—PSEN2—dilated cardiomyopathy	7.29e-06	7.43e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—AGTR1—dilated cardiomyopathy	7.27e-06	7.41e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—AGT—dilated cardiomyopathy	7.19e-06	7.32e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.18e-06	7.31e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—RAF1—dilated cardiomyopathy	7.17e-06	7.31e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.06e-06	7.2e-05	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	7.06e-06	7.2e-05	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—AGT—dilated cardiomyopathy	7.03e-06	7.16e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CXCL2—dilated cardiomyopathy	6.97e-06	7.1e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—AGTR2—dilated cardiomyopathy	6.97e-06	7.1e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	6.93e-06	7.06e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.89e-06	7.03e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	6.83e-06	6.97e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	6.75e-06	6.88e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—RAC1—dilated cardiomyopathy	6.68e-06	6.81e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.62e-06	6.75e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.56e-06	6.69e-05	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—AGT—dilated cardiomyopathy	6.53e-06	6.66e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.48e-06	6.6e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.48e-06	6.6e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CXCL2—dilated cardiomyopathy	6.47e-06	6.6e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—AGTR2—dilated cardiomyopathy	6.47e-06	6.6e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—AGT—dilated cardiomyopathy	6.38e-06	6.51e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.32e-06	6.45e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.28e-06	6.4e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	6.27e-06	6.39e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.22e-06	6.34e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—RAC1—dilated cardiomyopathy	6.21e-06	6.33e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.13e-06	6.25e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	6.08e-06	6.19e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.03e-06	6.15e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.02e-06	6.13e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—RAF1—dilated cardiomyopathy	6.01e-06	6.12e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—AGT—dilated cardiomyopathy	5.93e-06	6.04e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.92e-06	6.04e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	5.92e-06	6.04e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—GPX1—dilated cardiomyopathy	5.88e-06	6e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—GPX1—dilated cardiomyopathy	5.87e-06	5.98e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.83e-06	5.94e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.81e-06	5.93e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	5.77e-06	5.88e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—CD36—dilated cardiomyopathy	5.73e-06	5.84e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.72e-06	5.83e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—CD36—dilated cardiomyopathy	5.72e-06	5.83e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.47e-06	5.58e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—RAF1—dilated cardiomyopathy	5.45e-06	5.55e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—RAF1—dilated cardiomyopathy	5.44e-06	5.54e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.42e-06	5.53e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.4e-06	5.5e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.36e-06	5.46e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.36e-06	5.46e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—RAC1—dilated cardiomyopathy	5.35e-06	5.46e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.35e-06	5.45e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.28e-06	5.38e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	5.19e-06	5.29e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—AGT—dilated cardiomyopathy	5.16e-06	5.26e-05	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—AGT—dilated cardiomyopathy	5.15e-06	5.25e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—AGT—dilated cardiomyopathy	5.11e-06	5.21e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.08e-06	5.18e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.07e-06	5.16e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5e-06	5.09e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.99e-06	5.08e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.98e-06	5.07e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.92e-06	5.01e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—RAC1—dilated cardiomyopathy	4.88e-06	4.97e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—RAC1—dilated cardiomyopathy	4.83e-06	4.93e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—GPX1—dilated cardiomyopathy	4.78e-06	4.87e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—RAC1—dilated cardiomyopathy	4.77e-06	4.86e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.72e-06	4.81e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—AGT—dilated cardiomyopathy	4.66e-06	4.75e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—CD36—dilated cardiomyopathy	4.65e-06	4.74e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—AGT—dilated cardiomyopathy	4.62e-06	4.71e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—AGT—dilated cardiomyopathy	4.56e-06	4.65e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—RAC1—dilated cardiomyopathy	4.51e-06	4.6e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—RAC1—dilated cardiomyopathy	4.44e-06	4.53e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.43e-06	4.51e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—GPX1—dilated cardiomyopathy	4.39e-06	4.47e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.37e-06	4.45e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—AGT—dilated cardiomyopathy	4.31e-06	4.4e-05	CbGpPWpGaD
Carvedilol—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	4.29e-06	4.38e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—CD36—dilated cardiomyopathy	4.27e-06	4.36e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—AGT—dilated cardiomyopathy	4.24e-06	4.33e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—AGT—dilated cardiomyopathy	4.19e-06	4.27e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—GPX1—dilated cardiomyopathy	4.14e-06	4.22e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—EGFR—dilated cardiomyopathy	4.12e-06	4.2e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.12e-06	4.19e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.06e-06	4.14e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—CD36—dilated cardiomyopathy	4.03e-06	4.11e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—RAC1—dilated cardiomyopathy	3.95e-06	4.02e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—AGT—dilated cardiomyopathy	3.85e-06	3.92e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—AGT—dilated cardiomyopathy	3.77e-06	3.84e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.75e-06	3.83e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—EGFR—dilated cardiomyopathy	3.74e-06	3.81e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—EGFR—dilated cardiomyopathy	3.73e-06	3.8e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.72e-06	3.79e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.67e-06	3.74e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—RAC1—dilated cardiomyopathy	3.67e-06	3.74e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—AGT—dilated cardiomyopathy	3.63e-06	3.7e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—RAF1—dilated cardiomyopathy	3.55e-06	3.62e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—AGT—dilated cardiomyopathy	3.5e-06	3.57e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.47e-06	3.54e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.42e-06	3.49e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	3.3e-06	3.37e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—RAF1—dilated cardiomyopathy	3.23e-06	3.3e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—CD36—dilated cardiomyopathy	3.22e-06	3.28e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—RAF1—dilated cardiomyopathy	3.2e-06	3.27e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—RAF1—dilated cardiomyopathy	3.16e-06	3.22e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	3.11e-06	3.17e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	3.09e-06	3.15e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.04e-06	3.1e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	3.03e-06	3.09e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	3.01e-06	3.06e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—RAF1—dilated cardiomyopathy	2.99e-06	3.05e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—RAF1—dilated cardiomyopathy	2.95e-06	3e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—AGT—dilated cardiomyopathy	2.9e-06	2.95e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.82e-06	2.88e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	2.73e-06	2.78e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	2.71e-06	2.76e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	2.64e-06	2.69e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—RAF1—dilated cardiomyopathy	2.62e-06	2.67e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	2.57e-06	2.62e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EGFR—dilated cardiomyopathy	2.43e-06	2.48e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—RAF1—dilated cardiomyopathy	2.43e-06	2.48e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	2.31e-06	2.36e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EGFR—dilated cardiomyopathy	2.22e-06	2.26e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EGFR—dilated cardiomyopathy	2.2e-06	2.24e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EGFR—dilated cardiomyopathy	2.17e-06	2.21e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EGFR—dilated cardiomyopathy	2.05e-06	2.09e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	2.04e-06	2.07e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EGFR—dilated cardiomyopathy	2.02e-06	2.06e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	1.98e-06	2.02e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EGFR—dilated cardiomyopathy	1.79e-06	1.83e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	1.78e-06	1.82e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EGFR—dilated cardiomyopathy	1.67e-06	1.7e-05	CbGpPWpGaD
